A new treatment for corneal scarring is being developed by University of Houston optometry researcher Tarsis G. Ferreira. The treatment uses a natural protein called decorin to block scarring and unwanted blood vessel growth, offering hope for people with injured corneas.
Researchers discovered that statins selectively modulate key components of the Wnt/β-catenin signaling pathway, leading to lower levels of tumor-promoting proteins and cancer-suppressing cellular behaviors. Statins downregulate SATB1 while increasing SATB2, making cancer cells less able to grow and spread.
Researchers at MURR have optimized Terbium-161 for radiopharmaceutical use, enabling targeted destruction of cancer cells with high-energy electrons. The breakthrough could add extra therapeutic effectiveness to existing treatments without requiring new drug development.
A recent study found that people in poorer areas receive three times the prescriptions for opioids than those in wealthier areas, despite a decline in overall opioid use in Canada. The research highlights the persistence of inequalities in healthcare and the need for targeted interventions to mitigate the risks of opioid misuse.
Chemotherapy-induced pyroptosis in bladder cancer can actually make the disease more resistant to treatment by fueling cancer stem cells. Blocking this inflammatory process with belnacasan may overcome chemoresistance in preclinical models.
The Be Well Texas initiative, led by the University of Texas Health Science Center at San Antonio, will expand access to opioid use disorder treatment services and recovery support across rural and urban communities. This major statewide expansion aims to reduce overdose deaths and build a lasting recovery infrastructure.
Researchers used an optogenetic platform to discover dozens of molecules that can act as pan-antivirals, including two chemical scaffolds that could serve as development candidates. The compounds were tested on Zika, Respiratory Syncytial Virus (RSV) and herpes, showing promising results.
Recent studies have revealed significant improvements in patient prognosis for chronic thromboembolic pulmonary hypertension (CTEPH) over the past few decades. Advances in surgical techniques, drug development, and multimodal therapies have led to increased treatment rates and improved survival rates among patients.
Scientists at University of South Australia developed a long-acting injectable formulation that delivers levodopa and carbidopa over a week, reducing the need for multiple daily tablets. The biodegradable formulation improves treatment outcomes and patient compliance, offering a potential game-changer for Parkinson's care.
A study from The University of Osaka reveals nearly half of patients with extracranial arteriovenous malformations carry mutations in the RAS/RAF/MAPK signaling pathway. These mutations were linked to abnormal vascular morphology and were frequently detected in younger female patients.
A new study highlights major hurdles for multinational clinical trials in Europe, including differences in timelines and processing times between countries. Researchers found that the UK made significant gains in efficiency during the pandemic, while non-UK countries lagged behind.
A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.
UVA Health received two anonymous $25 million estate gifts to support the Paul and Diane Manning Institute of Biotechnology. The institute will develop new treatments for hard-to-treat diseases with a state-of-the-art biomedical research facility expected to drive economic growth in Central Virginia.
A recent study published in The American Journal of Pathology has discovered that ADAM10 regulates abnormal blood vessel growth in the retina, which can cause vision loss or impairment. The findings suggest that targeting ADAM10 or its downstream effectors, such as Ephrin B2, may offer novel strategies for managing or preventing retina...
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
A comprehensive review highlights the impact of anti-cancer treatments on bone health, increasing the risk of fractures and bone fragility. The International Osteoporosis Foundation advocates for a multidisciplinary approach to early screening and proactive bone-protective strategies.
Scientists at Xi'an Jiaotong-Liverpool University developed a new nanoparticle capable of carrying high doses of chemotherapy drugs while staying stable for extended periods. This innovation could make treatments more effective and reduce side effects.
Researchers at UT Health San Antonio have made a major discovery in understanding cancer drug resistance, specifically in BRCA1-deficient cancers treated with PARP inhibitors. The study reveals that problems in the CST complex can cause resistance to these drugs, opening doors to new therapies and personalized treatments.
A Rutgers Health study reveals that ciprofloxacin accelerates antibiotic resistance by triggering energy crisis in E. coli cells, allowing them to survive and mutate faster. The discovery highlights the need for new strategies in antibiotic development and use.
A new study found that taking antipsychotic medication as prescribed significantly reduces the odds of a motor vehicle crash among drivers with schizophrenia. Researchers analyzed 20 years of data and found a 50% reduction in crash risk among those who adhered to their medication.
A large cohort study has shown that supplementary treatment with statins can boost survival chances for critically ill patients with sepsis. The results indicate a 39% lower death rate over 28 days after hospital admission.
Researchers have discovered that nicotinamide riboside supplementation significantly improves NAD+ levels, reducing arterial stiffness, skin ulcer area, and kidney dysfunction. This breakthrough offers new hope for patients with Werner syndrome who lack effective treatment options.
A large study has found that cholesterol-lowering drugs do not have an antidepressive effect, contradicting previous small studies. The research, published in JAMA Psychiatry, involved 161 patients with depression and obesity, who received either statins or a placebo for 12 weeks.
A study published in The Journal of Pain found that nature exposure can help people with chronic lower back pain by providing a sense of escapism, social connection, and physical exercise. Researchers recommend incorporating accessible design features into natural spaces to improve inclusivity.
A new study published by Martin-Luther-Universität Halle-Wittenberg found that theophylline significantly improved symptoms and quality of life for patients with ADCY5-related dyskinesia. The treatment yielded impressive results, including reduced muscle twitches, improved gait, and better psychosocial well-being.
Exposure to PM2.5 air pollutants impairs mucociliary clearance, a key protective mechanism in the respiratory tract, leading to severe airway damage and respiratory diseases. Researchers have identified the enzyme ALDH1A1 as a potential therapeutic target to reverse this damage and strengthen our respiratory defenses.
A Virginia Tech professor has received a proof-of-concept grant to further develop a chemical compound that could help promote weight loss by increasing mitochondrial activity. The compound, named BAM15, shows promise in preclinical studies without affecting food intake or muscle mass.
The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.
A study found that prescribing guideline-directed medical treatment to patients 90 years and older following their first heart attack can improve survival rates. The greatest benefit was observed in those who received all four recommended therapies, including beta-blockers and renin-angiotensin-aldosterone system inhibitors.
A new study finds that cannabis use disorder diagnoses rose substantially across all age groups, race/ethnicity, and comorbidity subgroups nationwide from 2000 to 2022. People living with HIV experienced the greatest relative increase in CUD diagnoses, particularly among older adults.
Researchers at The University of Osaka found that localized oxygen deficiency in colon tumors can promote tumor growth by transforming normal fibroblasts into inflammatory fibroblasts. These altered cells release factors that help tumors grow, offering a potential new target for cancer therapy.
A large cohort study found that early antibiotic treatment did not significantly improve outcomes for patients with nonsevere COVID-19. The results argue against routine antibiotic use in this population due to associated risks.
A breakthrough all-oral treatment for a rare but deadly strain of sleeping sickness is now available, revolutionizing care for patients in endemic countries. Fexinidazole Winthrop has been approved for use in several African countries and is being distributed by WHO, offering a safer alternative to existing treatments.
A new study published at the European Congress on Obesity suggests that GLP-1 agonist drugs can lead to a clinically relevant change in BMI for children with severe obesity. In this study, 30% of children who received GLP-1 drugs experienced a significant reduction in BMI, compared to around 27% of those who did not receive them.
A systematic review of 46 clinical studies with 4,113 participants found that automated insulin delivery (AID) systems improved time in target range and reduced elevated glucose values compared to conventional pump therapy. However, low efficacy was observed during periods with very low glucose levels.
A new study found that only 39% of clinical trials report the race or ethnicity of participants involved. The research highlights the need for more comprehensive reporting and recruitment practices to ensure studies better reflect diverse populations globally. This is crucial for developing inclusive, effective, and equitable treatments.
The updated CDC HIV Non-Occupational Post Exposure Prophylaxis (nPEP) Guidelines aim to streamline medical practice and prevent new HIV infections. New guidelines include streamlined assessment factors, preferred nPEP regimens, and faster treatment initiation within 24 hours.
Despite slight increase in prescriptions between 2021 and 2024, only 3% of eligible patients received a prescription. Disparities were found based on race, ethnicity, social vulnerability, and urbanicity, with small but significant differences compared to overall underutilization.
Researchers developed promising α-synuclein PET tracers that can visualize protein aggregates in living patients, enabling earlier diagnosis and treatment monitoring. Tracers like [18F]C05-05 and [18F]ACI-12589 showed significant results in distinguishing synucleinopathies from healthy controls.
Researchers have developed three-dimensional spheroid cultures that better replicate cell-cell interactions and nutrient gradients, leading to a greater understanding of tumour tissue behaviour and drug responses. The study highlights the importance of mimicking tumour architecture in testing cancer therapies.
Researchers at University of Turku discovered a new biomarker that correlates the thickness of inflammatory cell rim surrounding brain lesions with disease severity and speed. The wider the rim, the more aggressively the disease advances, allowing for earlier treatment identification and evaluating drug candidates.
A cohort study of pregnant individuals with opioid use disorder found that buprenorphine treatment was associated with improved maternal and infant outcomes. The study highlights the need to improve access to treatment nationwide for these patients.
A phase III clinical trial found that adding pembrolizumab before and after surgery improved responses and survival in patients with previously untreated, locally advanced head and neck squamous cell carcinoma. Patients treated with pembrolizumab were at least 27% less likely to have experienced recurrence.
Scientists developed an injectable therapy that protects the heart from damage after a heart attack by blocking the interaction between two proteins, Keap1 and Nrf2. The study showed decreased inflammation, cell death, and improved cardiac function in animal models.
Researchers developed a new therapy that can be injected intravenously right after a heart attack to promote healing and prevent heart failure. The therapy both prompts the immune system to encourage tissue repair and promotes survival of heart muscle cells after a heart attack, showing effectiveness up to five weeks after injection.
A new study reports on five patients with Canavan disease who have a novel variant identified through targeted long-read sequencing, revealing an SVA_E retrotransposable element that disrupts gene function. The findings enhance genetic diagnostics and enable improved guidance for families.
A new study finds that radioiodine therapy significantly increases relative survival rates in differentiated thyroid cancer patients, with benefits observed across low-, intermediate-, and high-risk subgroups. The treatment reduces recurrence rates and improves long-term survival in high-risk groups, while also showing promise for low-...
A Phase 3 clinical trial has shown that a combination of sotorasib and panitumumab significantly improves progression-free survival in patients with KRAS G12C metastatic colorectal cancer. The study found improved overall survival rates, with the high-dose sotorasib group experiencing a 30% prolongation compared to standard care.
This review compares the bioactive components and medicinal properties of natural and cultivated O. sinensis, highlighting differences in composition and effectiveness for specific therapeutic uses. Polysaccharides, nucleosides, sterols, and amino acids contribute to their health benefits, with natural specimens often exhibiting higher...
Researchers developed a new model called React-OT that can predict the transition state of chemical reactions in under a second with high accuracy. The model uses linear interpolation to generate better initial guesses, reducing the number of steps and computation time needed.
Researchers developed an AI platform that tracks cancer biomarkers to personalize treatment dose adjustments for patients with advanced solid tumors. The study resulted in optimal doses being administered to 97.2% of patients, with average reductions of 20%.
A new study found that both oral and injectable forms of naltrexone are effective in reducing heavy drinking among hospitalized patients. The medication was administered before discharge, resulting in a significant decrease in heavy drinking within the last 30 days of the three-month follow-up period.
A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.
A study by Johns Hopkins Medicine found that older adults with cancer benefit equally from immunotherapy treatments as younger patients, with key differences in their immune responses and cells. Researchers hope to develop new therapies tailored to different age groups' needs and improve treatment success.
Researchers from Radboud University Medical Center found that an existing drug can revive immune cells paralyzed by sepsis, a leading cause of death in ICUs. The study provides new perspectives for the treatment of sepsis and may lead to potential treatments for patients with immune paralysis.
Researchers at Penn's School of Dental Medicine and Perelman School of Medicine found that ACE inhibitors can inhibit the activity of ACE2, a critical cardioprotective enzyme. This discovery has implications for human patients prescribed these medications, who may benefit from additional ACE2 treatment.
Researchers at Duke University and colleagues discover a way to improve the uptake of cancer-fighting drugs called PROTACs by leveraging the CD36 protein. This approach delivered up to 23 times more potent treatment without compromising stability or solubility, paving the way for effective medications.
A UC Riverside-led study found that adult stem cells rely on histone chaperones to maintain their regenerative capacity. The researchers discovered that disrupting these proteins can lead to specific changes in stem cell identity, potentially guiding them into desired cell types.
Aging-associated mutations in the Dnmt3a gene boost mitochondria power in blood stem cells, leading to clonal hematopoiesis. New mitochondrial-targeting drugs show promise in treating age-related illnesses by selectively weakening mutated cells without impacting normal ones.
Research found that certain diabetes medications associated with weight loss can contribute to muscle mass loss and increased risk of falls. The study identified three significant risk factors for falls: history of falls, use of SGLT2 inhibitors, and advanced age.